ERBB2 and cholangiocarcinoma: Data were too limited in KAMELEON to draw conclusions regarding the efficacy of HER2‐targeted therapy in advanced pancreatic cancer or cholangiocarcinoma, but one patient with pancreatic cancer experienced PR following treatment with T‐DM1.